Healing of segmental bone defects by direct percutaneous gene delivery: Effect of vector dose

Volker M. Betz, Oliver B. Betz, Vaida Glatt, Louis C. Gerstenfeld, Thomas A. Einhorn, Mary L. Bouxsein, Mark S. Vrahas, Christopher H Evans

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Previous studies have demonstrated the ability of direct adenoviral BMP-2 (Ad.BMP-2) gene delivery to enhance bone repair. Nevertheless, in studies using a rat segmental defect model, it has not proved possible to achieve reliably full osseous union in all animals. To address this issue, we evaluated the effect of vector dose on healing. Critical-size defects were created in the right femora of 27 Sprague-Dawley rats. The defects received a single, intralesional, percutaneous injection of 2.7 × 107 (low dose), 2.7 × 108 (medium dose), or 2.7 × 109 (high dose) plaque-forming units of Ad.BMP-2. After 8 weeks, femora were evaluated by X-ray, dual-energy X-ray absorptiometry, microcomputed tomography (μCT), and histology. The high dose of vector bridged 100%, the medium dose 11%, and the low dose 25% of the defects, as evaluated by X-ray and μCT imaging. Bone mineral content and bone volume of the defects receiving the high dose of vector were significantly higher than those of both groups receiving lower doses. Histologically, defects treated with the high dose were filled by trabecular bone and small amounts of cartilage, whereas large areas of fibrous tissue and cartilage remained in the defects receiving lower doses. However, the newly formed bone lacked the structural organization of native bone, suggesting that further maturation is necessary.

Original languageEnglish (US)
Pages (from-to)907-915
Number of pages9
JournalHuman Gene Therapy
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Bone and Bones
Femur
Genes
Cartilage
Intralesional Injections
X-Ray Microtomography
X Ray Computed Tomography
Photon Absorptiometry
Bone Density
Sprague Dawley Rats
Histology
X-Rays
Cancellous Bone

ASJC Scopus subject areas

  • Genetics

Cite this

Betz, V. M., Betz, O. B., Glatt, V., Gerstenfeld, L. C., Einhorn, T. A., Bouxsein, M. L., ... Evans, C. H. (2007). Healing of segmental bone defects by direct percutaneous gene delivery: Effect of vector dose. Human Gene Therapy, 18(10), 907-915. https://doi.org/10.1089/hum.2007.077

Healing of segmental bone defects by direct percutaneous gene delivery : Effect of vector dose. / Betz, Volker M.; Betz, Oliver B.; Glatt, Vaida; Gerstenfeld, Louis C.; Einhorn, Thomas A.; Bouxsein, Mary L.; Vrahas, Mark S.; Evans, Christopher H.

In: Human Gene Therapy, Vol. 18, No. 10, 01.10.2007, p. 907-915.

Research output: Contribution to journalArticle

Betz, VM, Betz, OB, Glatt, V, Gerstenfeld, LC, Einhorn, TA, Bouxsein, ML, Vrahas, MS & Evans, CH 2007, 'Healing of segmental bone defects by direct percutaneous gene delivery: Effect of vector dose', Human Gene Therapy, vol. 18, no. 10, pp. 907-915. https://doi.org/10.1089/hum.2007.077
Betz VM, Betz OB, Glatt V, Gerstenfeld LC, Einhorn TA, Bouxsein ML et al. Healing of segmental bone defects by direct percutaneous gene delivery: Effect of vector dose. Human Gene Therapy. 2007 Oct 1;18(10):907-915. https://doi.org/10.1089/hum.2007.077
Betz, Volker M. ; Betz, Oliver B. ; Glatt, Vaida ; Gerstenfeld, Louis C. ; Einhorn, Thomas A. ; Bouxsein, Mary L. ; Vrahas, Mark S. ; Evans, Christopher H. / Healing of segmental bone defects by direct percutaneous gene delivery : Effect of vector dose. In: Human Gene Therapy. 2007 ; Vol. 18, No. 10. pp. 907-915.
@article{8bc03f8e61564aec99394abd87094f8b,
title = "Healing of segmental bone defects by direct percutaneous gene delivery: Effect of vector dose",
abstract = "Previous studies have demonstrated the ability of direct adenoviral BMP-2 (Ad.BMP-2) gene delivery to enhance bone repair. Nevertheless, in studies using a rat segmental defect model, it has not proved possible to achieve reliably full osseous union in all animals. To address this issue, we evaluated the effect of vector dose on healing. Critical-size defects were created in the right femora of 27 Sprague-Dawley rats. The defects received a single, intralesional, percutaneous injection of 2.7 × 107 (low dose), 2.7 × 108 (medium dose), or 2.7 × 109 (high dose) plaque-forming units of Ad.BMP-2. After 8 weeks, femora were evaluated by X-ray, dual-energy X-ray absorptiometry, microcomputed tomography (μCT), and histology. The high dose of vector bridged 100{\%}, the medium dose 11{\%}, and the low dose 25{\%} of the defects, as evaluated by X-ray and μCT imaging. Bone mineral content and bone volume of the defects receiving the high dose of vector were significantly higher than those of both groups receiving lower doses. Histologically, defects treated with the high dose were filled by trabecular bone and small amounts of cartilage, whereas large areas of fibrous tissue and cartilage remained in the defects receiving lower doses. However, the newly formed bone lacked the structural organization of native bone, suggesting that further maturation is necessary.",
author = "Betz, {Volker M.} and Betz, {Oliver B.} and Vaida Glatt and Gerstenfeld, {Louis C.} and Einhorn, {Thomas A.} and Bouxsein, {Mary L.} and Vrahas, {Mark S.} and Evans, {Christopher H}",
year = "2007",
month = "10",
day = "1",
doi = "10.1089/hum.2007.077",
language = "English (US)",
volume = "18",
pages = "907--915",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Healing of segmental bone defects by direct percutaneous gene delivery

T2 - Effect of vector dose

AU - Betz, Volker M.

AU - Betz, Oliver B.

AU - Glatt, Vaida

AU - Gerstenfeld, Louis C.

AU - Einhorn, Thomas A.

AU - Bouxsein, Mary L.

AU - Vrahas, Mark S.

AU - Evans, Christopher H

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Previous studies have demonstrated the ability of direct adenoviral BMP-2 (Ad.BMP-2) gene delivery to enhance bone repair. Nevertheless, in studies using a rat segmental defect model, it has not proved possible to achieve reliably full osseous union in all animals. To address this issue, we evaluated the effect of vector dose on healing. Critical-size defects were created in the right femora of 27 Sprague-Dawley rats. The defects received a single, intralesional, percutaneous injection of 2.7 × 107 (low dose), 2.7 × 108 (medium dose), or 2.7 × 109 (high dose) plaque-forming units of Ad.BMP-2. After 8 weeks, femora were evaluated by X-ray, dual-energy X-ray absorptiometry, microcomputed tomography (μCT), and histology. The high dose of vector bridged 100%, the medium dose 11%, and the low dose 25% of the defects, as evaluated by X-ray and μCT imaging. Bone mineral content and bone volume of the defects receiving the high dose of vector were significantly higher than those of both groups receiving lower doses. Histologically, defects treated with the high dose were filled by trabecular bone and small amounts of cartilage, whereas large areas of fibrous tissue and cartilage remained in the defects receiving lower doses. However, the newly formed bone lacked the structural organization of native bone, suggesting that further maturation is necessary.

AB - Previous studies have demonstrated the ability of direct adenoviral BMP-2 (Ad.BMP-2) gene delivery to enhance bone repair. Nevertheless, in studies using a rat segmental defect model, it has not proved possible to achieve reliably full osseous union in all animals. To address this issue, we evaluated the effect of vector dose on healing. Critical-size defects were created in the right femora of 27 Sprague-Dawley rats. The defects received a single, intralesional, percutaneous injection of 2.7 × 107 (low dose), 2.7 × 108 (medium dose), or 2.7 × 109 (high dose) plaque-forming units of Ad.BMP-2. After 8 weeks, femora were evaluated by X-ray, dual-energy X-ray absorptiometry, microcomputed tomography (μCT), and histology. The high dose of vector bridged 100%, the medium dose 11%, and the low dose 25% of the defects, as evaluated by X-ray and μCT imaging. Bone mineral content and bone volume of the defects receiving the high dose of vector were significantly higher than those of both groups receiving lower doses. Histologically, defects treated with the high dose were filled by trabecular bone and small amounts of cartilage, whereas large areas of fibrous tissue and cartilage remained in the defects receiving lower doses. However, the newly formed bone lacked the structural organization of native bone, suggesting that further maturation is necessary.

UR - http://www.scopus.com/inward/record.url?scp=35348876799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348876799&partnerID=8YFLogxK

U2 - 10.1089/hum.2007.077

DO - 10.1089/hum.2007.077

M3 - Article

C2 - 17910523

AN - SCOPUS:35348876799

VL - 18

SP - 907

EP - 915

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 10

ER -